Citations

Clear

941 citation(s) found for "Tefferi, A".

Pathogenesis of Myelofibrosis With Myeloid Metaplasia
Tefferi, Ayalew

Mayo Clinic

Journal of Clinical Oncology | November 18, 2005 | Volume: 23 | Issue: 33 | Pages: 8520-8530

10.1200/jco.2004.00.9316 | PMID 16293880 Get It

The primary disease process in myelofibrosis with myeloid metaplasia (MMM) is clonal myeloproliferation with varying degrees of phenotypic differentiation. This is characteristically accompanied by secondary intramedullary collagen fibrosis, osteosclerosis, angiogenesis, and extramedullary hematopoiesis. Modern clonality studies have confirmed the multipotent stem-cell origin of the neoplastic process in MMM. The nature of the specific oncogenic mutation(s) is currently being unraveled with the recent discovery of an association between a somatic point mutation of JAK2 tyrosine kinase (V617F) and bcr/abl-negative myeloproliferative disorders, including MMM. The pathogenetic mechanisms that underlie the secondary bone marrow stromal changes in MMM are also incompletely understood. Mouse models of this latter disease aspect have been constructed by either in vivo overexpression of thrombopoietin (TPOhighmice) or megakaryocyte lineage restricted underexpression of the transcription factor GATA-1 (GATA-1lowmice). Gene knockout experiments using such animal models have suggested the essential role of hematopoietic cell-derived transforming growth factor beta1 in inducing bone marrow fibrosis and stromal cell–derived osteoprotegerin in promoting osteosclerosis. However, experimental myelofibrosis in mice does not recapitulate clonal myeloproliferation that is fundamental to human MMM. Other cytokines that are implicated in mediating myelofibrosis and angiogenesis in MMM include basic fibroblast, platelet-derived, and vascular endothelial growth factors. It is currently assumed that such cytokines are abnormally released from clonal megakaryocytes as a result of a pathologic interaction with neutrophils (eg, emperipolesis). This latter phenomenon, through neutrophil-derived elastase, could also underlie the abnormal peripheral-blood egress of myeloid progenitors in MMM.
V617F “JAKs” up myeloproliferative signal
Tefferi, Ayalew

Mayo Clinic

Blood | November 2, 2005 | Volume: 106 | Issue: 10 | Pages: 3335-3336

10.1182/blood-2005-08-3352 Get It

Gefitinib adopts orphan kinases in leukemia
Pardanani, Animesh , Tefferi, Ayalew

Mayo Clinic

Blood | October 3, 2005 | Volume: 106 | Issue: 8 | Pages: 2600-2601

10.1182/blood-2005-07-3008 Get It

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes
Steensma, David P. , Dewald, Gordon W., Powell, Heather L., McClure, Rebecca F., Levine, Ross L. , Gilliland, D. Gary, Tefferi, Ayalew , Lasho, Terra L. , Steensma, David P

Mayo Clinic

Blood | April 29, 2005 | Volume: 106 | Issue: 4 | Pages: 1207-1209

10.1182/blood-2005-03-1183 | PMID 15860661 Get It

AbstractA somatic mutation in the JH2 autoinhibitory domain of the Janus kinase 2 (JAK2) tyrosine kinase was recently described in polycythemia vera, essential thrombocythemia, and myelofibrosis with myeloid metaplasia. The prevalence of this mutation in either “atypical” myeloproliferative disorders (MPDs) or the myelodysplastic syndromes (MDSs) is unknown. Bone marrow–derived genomic DNA from 245 patients—119 with chronic myelomonocytic leukemia (CMML), 101 with MDS, 11 with hypereosinophilic syndrome (HES), 8 with systemic mastocytosis (SM), and 6 with chronic neutrophilic leukemia (CNL)—was screened for the JAK2 V617F mutation. A mutant allele was detected in 11 patients: 3 with CMML (3%), 5 with MDS (5%), 2 with SM, and 1 with CNL. Interestingly, one of the patients with SM and the patient with CNL with JAK2 V617F had a history of lymphoma, and this patient with SM also had associated myelofibrosis and CMML. The current observation strengthens the specific association between JAK2 V617F and classic MPD, but also suggests an infrequent occurrence in other myeloid disorders.
Detection of Aberrant Gene Expression in CD34 + Hematopoietic Stem Cells from Patients with Agnogenic Myeloid Metaplasia Using Oligonucleotide Microarrays
Jones, Letetia C., Tefferi, Ayalew , Vuong, Peter T., Desmond, Julian C., Hofmann, Wolf‐K., Koeffler, H. Phillip

Mayo Clinic

STEM CELLS | April 22, 2005 | Volume: 23 | Issue: 5 | Pages: 631-637

10.1634/stemcells.2004-0131 | PMID 15849170 Get It

Myelofibrosis with Myeloid Metaplasia: New Developments in Pathogenesis and Treatment
Dingli, David , Tefferi, Ayalew , Mesa, Ruben A. , Dingli, David

Mayo Clinic

Internal Medicine | March 4, 2005 | Volume: 43 | Issue: 7 | Pages: 540-547

10.2169/internalmedicine.43.540 | PMID 15335177 Get It

Mutant Kit: thwarting the message down below
Tefferi, Ayalew

Mayo Clinic

Blood | March 3, 2005 | Volume: 105 | Issue: 6 | Pages: 2240-2241

10.1182/blood-2004-12-4827 Get It

Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases
Li, Chin‐Yang, Ketterling, Rhett P. , Schroeder, Georgene, Knudson, Ryan A., Tefferi, Ayalew , Mesa, Ruben A. , Li, Chin‐Yang, Ketterling, Rhett P

Mayo Clinic

Blood | September 24, 2004 | Volume: 105 | Issue: 3 | Pages: 973-977

10.1182/blood-2004-07-2864 | PMID 15388582 Get It

Abstract Among 2333 consecutive patients with myelofibrosis with myeloid metaplasia (MMM) seen at our institution, 91 fulfilled the World Health Organization (WHO) criteria for leukemic transformation (LT). All episodes of LT were myeloid in origin (acute myeloid leukemia [AML]) with all French-American-British (FAB) subtypes represented except M3; the most frequent subtypes were M7 (25.4%), M0 (22.4%), and M2 (17.9%). Cytogenetic studies during LT were available in 56 patients and revealed a clonal abnormality in 51 (91%): 30 patients had complex karyotype, 2 had core-binding factor gene lesions, and 18 had abnormalities of chromosome 5 or 7. Karyotypic evolution was documented in the majority of the patients in whom serial analysis was possible. In general, LT was fatal in 98% of the cases after a median of 2.6 months (range, 0-24.2 months). Twenty-four patients received AML-like induction chemotherapy that resulted in no complete remission: 41% reverted into chronic-phase disease and the incidence of treatment-related mortality was 33%. The remaining 67 patients received either supportive care alone (48 patients) or low-intensity chemotherapy (19 patients). Overall, survival was similarly poor in all 3 treatment categories. The outcome of LT in MMM with current therapies is dismal and either supportive care alone or appropriate clinical trials should be considered.
Angiogenesis and Anti-angiogenic Therapy in Myelofibrosis with Myeloid Metaplasia
Arora, Brijesh, Tefferi, Ayalew , Mesa, Ruben A.

Mayo Clinic

Leukemia & Lymphoma | September 10, 2004 | Volume: 45 | Issue: 12 | Pages: 2373-2386

10.1080/10428190400003267 | PMID 15621750 Get It

The Forgotten Myeloproliferative Disorder: Myeloid Metaplasia
Tefferi, Ayalew

Mayo Clinic

The Oncologist | August 24, 2004 | Volume: 8 | Issue: 3 | Pages: 225-231

10.1634/theoncologist.8-3-225 | PMID 12773744 Get It

AbstractLearning ObjectivesAfter completing this course, the reader will be able to:Derive a conceptual understanding of the classification as well as the pathogenesis of chronic myeloproliferative disorders with emphasis on myelofibrosis with myeloid metaplasia. Recognize how myelofibrosis with myeloid metaplasia is diagnosed and know what the differential diagnosis constitutes. Be familiar with current therapeutic options in myelofibrosis with myeloid metaplasia.Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.comMyelofibrosis with myeloid metaplasia is a hematologic disorder currently classified with polycythemia vera and essential thrombocythemia as a chronic myeloproliferative disease. The median age at diagnosis is 60 years, and more than 90% of patients are diagnosed after age 40 years. Clinical manifestations include massive splenomegaly, progressive anemia, profound constitutional symptoms, and extramedullary hematopoiesis. The diagnosis is confirmed by bone marrow examination after other causes of myelofibrosis are ruled out. Median survival is 5 years and causes of death include leukemic transformation. Prognosis is adversely affected by the presence of anemia (hemoglobin <10 g/dl), leukopenia or leukocytosis (white blood cells >30,000/μl), circulating blasts, and hypercatabolic symptoms. Conventional treatment is palliative and does not improve survival. In this regard, androgen preparations, corticosteroids, and erythropoietin are useful for the treatment of disease-associated anemia. Symptomatic splenomegaly is best managed by cytoreductive therapy or surgical removal. Radiation therapy is most useful in the treatment of nonhepatosplenic extramedullary hematopoiesis. New treatment approaches include the use of thalidomide alone or in combination with prednisone and hematopoietic stem cell transplantation.